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CASE REPORT
Ertapenem-induced delirium 
Francesca Farrugia, Marisa Abela
INTRODUCTION 
Ertapenem is an intravenous antibiotic within the class of 
carbapenem antibiotics which are highly effective against severe 
bacterial infections. These antibiotic agents exhibit a wider spectrum 
of action when compared to penicillins and cephalosporins despite 
carbapenems being part of the beta-lactam antibiotic class. 
CASE PRESENTATION 
The patient is an 85-year old gentleman who developed a lower 
urinary tract infection and left 4th toe osteomyelitis. Ertapenem was 
prescribed according to the sensitivities of the cultured organisms. 
After two weeks of antibiotic treatment the patient developed new-
onset delirium, agitation, hallucinations and throat discomfort. 
Ertapenem was stopped and the new symptoms resolved within 48 
hours.  
DISCUSSION 
 Delirium, agitation, hallucinations and throat discomfort are 
documented side-effects of ertapenem. In such cases the withdrawal 
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INTRODUCTION AND CASE PRESENTATION  
The patient is an 85-year old gentleman, a 
known case of peripheral vascular disease, 
currently a resident in a long term care facility, 
who developed pyuria and a wound exuding 
pus from the left 4th toe. Urinalysis, urine 
cultures, a wound swab and a left foot X-ray 
were taken. The urinalysis confirmed the 
presence of a urinary tract infection with 
urinalysis white blood cells of 500uL and 
positive urinalysis nitrites. The urine cultures 
showed a Klebsiella pneumoniae ESBL positive 
infection. The left 4th toe wound swab showed 
a methicillin resistant Staphylococcus aureus 
(MRSA) infection and 2 strains of coliforms 
including Proteus spp. The left foot X-ray 
showed cortical irregularity of the lateral side 
of the middle phalanx of the left 4th toe and 
osteopenia suggestive of early osteomyelitis.  
He had a normal renal function and an elevated 
C-reactive protein level of 90mg/L. 
Ertapenem 1g daily intravenous and 
clindamycin 300mg 6-hourly per oral were 
prescribed according to the microbiology 
results and antibiotic sensitivities. After two 
weeks of ertapenem therapy, the patient 
developed new-onset delirium, agitation, 
throat discomfort and hallucinations which 
had an acute onset over a period of 24 hours. 
The patient had no prior neurocognitive 
disorders. The physical examination was 
unremarkable and all the parameters were 
within normal limits. The left 4th toe wound 
showed clinical improvement with decreased 
erythema and no further pus exudation. The 
pyuria had resolved and the urine was now 
clear. An electrolyte profile and a renal 
function were all within normal limits. 
Ertapenem treatment was immediately 
discontinued and these symptoms all resolved 
within 48 hours.  
DISCUSSION 
Common side-effects of ertapenem include 
gastro-intestinal symptoms such as nausea, 
vomiting and diarrhoea, thrombophlebitis and 
skin reactions. Delirium and hallucinations are 
documented side-effects of ertapenem 
therapy and the frequency of such adverse 
reactions is unknown from data to date. 
Another rare documented adverse reaction 
includes encephalopathy.1 The Naranjo 
algorithm was used to assess the probability of 
the symptoms being secondary to an adverse 
drug reaction.2 The score for this patient was 3 
which indicated a possible adverse reaction to 
ertapenem with a dramatic improvement in 
the patient’s mental status upon the 
discontinuation of the drug. This patient had 
been taking the drug for 14 days, with the 
symptoms occurring only at the end of the 
recommended 14-day course of ertapenem for 
the Klebsiella pneumoniae lower urinary tract 
infection.  
The risk factor which may have predisposed 
this gentleman to these adverse reactions was 
his chronological age. The main patient-related 
risk factors for carbapenem-induced 
neurotoxicity are renal failure, low body 
weight, a history of cerebrovascular disease 
and advanced age.3 Carbapenem-induced 
neurotoxicity occurs via interactions with the 
ϒ-amino butyric acid receptor A (GABAA).4,5 The 
interaction happens through the C-2 side-chain 
of the carbapenem nucleus. 
Pharmacovigilance is of utmost importance in 
the monitoring and assessment of adverse 
drug reactions. It enables the identification of 
hazards related to pharmaceutical drugs and 
provides for the minimisation of harm that may 
occur to patients. Individual case safety 
reports with an identifiable patient and 
reporter, a suspected drug and the adverse 
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event are crucial in providing more 
information to the relevant Medicines 
Authority to investigate and examine adverse 
reactions related to the particular drug.  
CONCLUSIONS 
We are presenting this case report in order to 
highlight the possible neurologic adverse 
reactions of ertapenem. The identification and 
discontinuation of ertapenem as the cause of 
the delirium, hallucinations, agitation and 
throat discomfort in this gentleman brought 
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